← Back to Analyst Consensus 
TRAX Buy
First Tracks Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 50% |
| Oct 13, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Oct 13, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Oct 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Sep 30, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Sep 18, 2026 | Evercore ISI Group | initiate | — → Outperform | — | 58% |
| Sep 16, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Sep 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 13, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 13, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 13, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Aug 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 10, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jul 28, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 28, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 21, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 8, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| May 4, 2026 | Piper Sandler | initiate | — → Overweight | — | 54% |
| Apr 28, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Apr 24, 2026 | Leerink Partners | initiate | — → Outperform | — | 50% |
| Apr 23, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Apr 22, 2026 | Barclays | initiate | — → Overweight | — | 53% |
| Apr 21, 2026 | UBS | initiate | — → Buy | — | 54% |
Price Target Trend
Apr 24, 2026 Oct 26, 2026
EPS Estimates
+1y —
0y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days